Business Wire

Rapid Multiplexing with Opal® Research Kits Now Available on LabSat™ Platform

23.5.2019 13:30:00 EEST | Business Wire | Press release

Share

Lunaphore Technologies S.A., a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics, announces a new rapid multiplexing application for its LabSat™ Research instrument.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190523005082/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FFPE IF of tonsil, 6-plex + DAPI. Total staining time: 4h12 (with Opal® 7-Color Manual IHC Kit) (Photo: Business Wire)

Following the signature of a co-marketing agreement between Lunaphore Technologies S.A. and Akoya Biosciences, Inc.; Lunaphore will start providing multiplexing protocols using Akoya’s Opal® immunoassay kits for its staining platform LabSat™ Research, Lunaphore’s first solution to reach the market.

LabSat™ is shown to perform rapid tests on tissue samples under 2.5 hours for a 3-plex plus counterstaining with the Opal® 4-Color Manual IHC Kit; and under 4.5 hours for a 6-plex plus counterstaining with the Opal® 7-Color Manual IHC Kit1. These timeframes present a 3 to 4-fold time improvement compared to the current turnaround times for Opal® 7-Color kit using manual protocols or other automation standards. During the study conducted by both companies, comparable intensity to other staining methods was observed, while reproducibility presented less than 20% of variability1. Moreover, uniformity throughout the tissue section was tested with excellent results, obtaining a signal gradient under 10% over 1 cm of tissue1. This opens opportunities for users to analyze images and quantify signals using Akoya’s imaging and software tools.

These short turnaround times are achieved thanks to a novel microfluidic tissue processor lying at the core of Lunaphore’s innovation, which allows researchers to perform rapid cycles of optimization in order to reach and repeat the desired multiplexed stainings, without the need to invest in traditional workflow automation instruments.

Lunaphore’s co-founder and CTO, Diego G. Dupouy, said: ”The great stainings obtained with our platform are the result of team effort by Lunaphore and Akoya, as we push both of our technologies to the next level. Our goal is to combine short turnaround times with high-quality stainings in order to enable researchers to develop their own immunophenotyping panels in unprecedented times.”

With the arrival of ultra-rapid automated multiplexing in LabSat™, Lunaphore brings together state-of-the-art multiplexing techniques, the high reproducibility of automation systems and an unmatched speed performance, now at the reach of medium and small laboratories.

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company developing next generation tissue autostainers. The award-winning technology based on microfluidics is called FFeX (Fast Fluidic Exchange). It aims to perform assays much faster than standard techniques and has demonstrated good results in tests with cancer patient samples. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue diagnostics and has been recognized as one of the most innovative companies nationally and internationally.

About LabSat™ Research

LabSat™ Research is a single-slide, ultra-rapid reagent delivery system performing IHC/IF tests on tissue samples for Research Use Only. The breakthrough speed performance of the device is achieved thanks to a novel microfluidic tissue processor lying at the core of Lunaphore’s innovation. This patented technology enables high precision tissue staining, with a drastic reduction of reagent incubation times.

About IHC/IF and multiplexing

Immunohistochemistry (IHC) staining is a technique that involves the use of antibodies to detect the presence of specific cancer biomarkers on a tissue sample. During an IHC test, the tissue is stained with labelled antibodies, producing a coloring on the tissue that is observable with a bright-field microscope. This coloring or staining will signal the presence and localization of specific cancer biomarkers within the tissue. Immunofluorescence (IF) is a similar technique which instead produces fluorescent stainings observable with a fluorescence microscope. IHC and IF are among the most common tests in immuno-oncology research to support scientists in the identification of specific cancer types.

In order to analyze the tumor microenvironment, understanding the spatial organization and co-expression of multiple biomarkers in a tissue section is of key importance. With this purpose, it is possible to stain and visualize several targets simultaneously with a technique known as multiplexed IHC or IF. With Akoya’s Opal® fluorescent kits -4-color and 7-color- 3 and 6 biomarkers, respectively, can be stained at once in order to maximize the obtention of information from each tissue section.

Disclaimer: LabSat™ Research is approved for Research Use Only and not available for diagnostic procedures. Only marketed in Europe.

1 Data on file.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Phone: +41 21 353 58 22

Andrea Büchler
Lunaphore Finance and Business Development
Email: andrea.buechler@lunaphore.com
Phone +41 79 598 40 73

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alushibe Holding Group to Bring 12 Global F&B Brands to Libya by 202829.10.2026 10:00:00 EET | Press release

Alushibe Holding Group today announced plans to bring 12 international food-and-beverage brands to Libya by 2028 through its Retail & Destinations division, beginning with an exclusive master franchise agreement with MADO, the Turkish ice-cream and patisserie house founded in 1850. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029822317/en/ Ahmed Gadalla signs exclusive master franchise agreement with Türkiye's MADO: US$7 million, 7 cafés and 350 jobs in the first phase; 1,000 sq m Benghazi flagship opens Q1 2027 – (Photo: AETOSWire) Signed in Kahramanmaraş on 13 October 2026 by Ahmed Gadalla, Founder and Chairman of Alushibe Holding Group, and Mehmet Sait Kanbur, Chairman of MADO, the agreement grants Alushibe exclusive rights to develop and operate MADO in Libya, the brand's 36th country. Alushibe will invest US$7 million in the first phase: 7 cafés and 350 jobs, beginning in Benghazi before Tripoli and other major cit

U.S. Bancorp Announces New U.S. Bancorp Global Funds Brand29.10.2026 10:00:00 EET | Press release

U.S. Bancorp today announced its new fund platform, U.S. Bancorp Global Funds, and its first offering, an offshore liquidity fund domiciled in Ireland, the U.S. Bancorp Liquidity – USD Treasury CNAV Fund. U.S. Bancorp Global Funds was created to support U.S. Bancorp’s growing international presence. It establishes a framework for future investment offerings and reflects U.S. Bancorp’s expanding presence in global markets. Investment products offered under the brand are established through U.S. Bancorp Global Funds ICAV, an Ireland-domiciled UCITS umbrella fund structure. The U.S. Bancorp Liquidity – USD Treasury CNAV Fund is the first offering introduced under the new brand. The U.S. Bancorp Liquidity – USD Treasury CNAV Fund is designed for investors outside the United States seeking to preserve capital while accessing a U.S. Treasury-focused liquidity solution within a regulated offshore structure. Domiciled in Ireland as a UCITS fund, it invests primarily in short-term U.S. Treasury

Element Biosciences Launches AVITI Dx™, Bringing CE-Marked IVD Sequencing to Ten EU Countries29.10.2026 10:00:00 EET | Press release

Element Biosciences, Inc. today announced the commercial launch of AVITI Dx, the company's first CE-marked in vitro diagnostic (IVD) sequencing platform under the European Union's In Vitro Diagnostic Regulation (EU IVDR). AVITI Dx integrates Element’s AVITI™ sequencing system, dedicated reagents, and software designed to meet applicable IVDR requirements and support regulated clinical laboratory workflows. The system is launching commercially in ten EU countries: the Netherlands, Germany, France, Italy, Spain, Austria, the Czech Republic, Latvia, Romania, and Poland, with additional markets planned through a phased approach. Developed and manufactured under Element's ISO 13485-certified quality management system, AVITI Dx is a Class A IVD sequencing system supported by IVDR-compliant reagents and software. Built on the same industry-leading ABC™ chemistry that powers Element's other solutions, AVITI Dx delivers the high-quality performance AVITI is known for, with the flexibility and s

Positively Languages Launches, Expands With Malta School and Opens New London Premises29.10.2026 10:00:00 EET | Press release

Positively Languages, a leading language learning business, is unveiling its new brand today. Formerly known as Kaplan Languages Group, (which Inspirit Capital acquired in May 2026), the business is also expanding its portfolio with the opening of a new school in Malta and a new premises in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028449595/en/ Positively Languages, formerly known as Kaplan Languages Group, has taught English, French and German to more than one million students from 140 countries over the past 20 years. The new brand name ‘Positively Languages’ is built around the principle that ‘experience moves you forward’ which forms the backbone of the future growth of the business; new products based on experiences, new schools in the heart of key cultural cities. Positively Languages is also excited to announce the opening of a new school on the Mediterranean island of Malta, known as Positively Langu

IQM Demonstrates Entanglement Across a Complete 54-Qubit Processor, Bringing Full-Chip Performance to Cloud Users29.10.2026 09:00:00 EET | Press release

IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced that its cloud-accessible IQM Emerald system has fully entangled all 54 qubits on the chip simultaneously, a result that shows the system’s computational quality holds up when every qubit is put to work at once. IQM’s cloud customers now have access to that same full-chip performance, so their computations can draw on the entire processor rather than a fraction of it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029191153/en/ IQM measured a fidelity of 0.515 at 40 qubits without readout error mitigation (REM) and 0.516 at the full 54 qubits with REM applied, both above the classical threshold of 0.500 that separates genuine entanglement from noise. These results rank among the strongest reported for any commercially available quantum computer, giving customers access to state-of-the-art, high-quality processors. U

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye